Anascorp Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to incidence of scorpion envenomation, emergency department utilization, effectiveness of antivenom therapy, government stockpiling programs, regional venom exposure risks.

The growth in the forecast period can be attributed to climate driven venom spread, improved emergency access, expansion of trauma centers, public health funding, increased awareness of venom treatment protocols. Major trends in the forecast period include continued demand for antivenom therapies, hospital based emergency toxicology care, focus on region specific envenomation, improved cold chain biologic handling, public health preparedness for venom incidents.

The increasing number of snakebite incidents is expected to drive the growth of the anascorp market in the coming years. Snakebite incidents involve situations in which individuals are bitten by snakes, often resulting in serious health risks that require immediate medical attention. The rise in snakebite cases is mainly attributed to factors such as urban expansion, climate change, human encroachment into snake habitats, limited access to healthcare facilities, and insufficient awareness and preventive measures. Anascorp, an advanced antivenom therapy, treats snakebite incidents by neutralizing venom from specific venomous snake species, thereby reducing the risk of severe symptoms, organ damage, or death. It is particularly valuable in regions with a high prevalence of snakebites, where timely and effective treatment is critical. For instance, in September 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 5.4 million snakebites occur each year, resulting in 81,410 to 137,880 deaths and numerous cases of permanent disability. Therefore, the increase in snakebite incidents is driving the growth of the anascorp market.

Rising healthcare expenditure is expected to support the growth of the anascorp market going forward. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatments, hospital care, pharmaceuticals, and public health programs, by governments, organizations, and individuals. The growth in healthcare spending is driven by the increasing prevalence of chronic diseases that require long-term and costly management. Higher healthcare expenditure improves the utilization of anascorp by expanding access to essential antivenom therapies, enabling healthcare facilities to better manage envenomation emergencies and reduce complications. It also supports investment in emergency care infrastructure, ensuring the timely availability of life-saving treatments in high-risk and underserved regions. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% higher growth compared to 2022. Therefore, rising healthcare expenditure is driving the growth of the anascorp market.

The increasing incidence of infectious diseases is expected to propel the growth of the anascorp market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. The rise in infectious disease cases is largely influenced by factors such as increased global travel, which facilitates the spread of pathogens, and declining vaccination rates, leading to the resurgence of previously preventable diseases such as measles. Anascorp is used in the treatment of envenomation from venomous snakebites by neutralizing venom, thereby preventing severe systemic effects and reducing the risk of secondary infections associated with tissue damage. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis cases in England increased to 4,850 in 2023, up from 4,380 cases in 2022, representing a 10.7% rise. Therefore, the rising incidence of infectious diseases is driving the growth of the anascorp market.

Major companies operating in the anascorp market are Instituto Bioclon S.A. de C.V.

North America was the largest region in the anascorp market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anascorp market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anascorp market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the anascorp market by raising costs related to biologic production inputs and plasma based manufacturing processes. These effects are most pronounced in hospitals and emergency care facilities across north america and parts of latin america. Higher import duties have influenced procurement budgets for antivenom stockpiles. Distribution logistics have also been affected by regulatory compliance at borders. However, tariffs are supporting localized biologics manufacturing and improving national emergency preparedness capabilities.

The anascorp market research report is one of a series of new reports that provides anascorp market statistics, including anascorp industry global market size, regional shares, competitors with a anascorp market share, detailed anascorp market segments, market trends and opportunities, and any further data you may need to thrive in the anascorp industry. This anascorp market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anascorp is a biopharmaceutical therapy used as an antivenom for the treatment of scorpion venom toxicity, particularly from hazardous species of Centruroides. It is produced through biological manufacturing processes and delivers critical treatment for individuals experiencing severe reactions following scorpion stings.

The primary product types in the anascorp market include human antivenoms, veterinary antivenoms, and combination antivenoms. Human antivenoms are therapeutic agents formulated to manage venomous bites or stings in humans. The clinical indications include scorpion stings and snake bites. The product is distributed through multiple sales channels, including direct sales, wholesalers, and online pharmacies, and is used by adult, geriatric, and pediatric patient populations.

The anascorp market consists of sales of products including Biosidus, ImmuVenom, Vins Bioproducts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.